Page 5 - Anti Fungal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2)
Basel, Switzerland, January 07, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that patient enrolment has been completed in the phase 3 study with the antifungal isavuconazole (Cresemba
), which is conducted in Japan by Basilea s partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma). The study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
1
David Veitch, Chief Executive Officer of Basilea, said: The completion of patient enrolment in the phase 3 study is an important step in the development of Cresemba in Japan, where we see one of the commercially most important opportunities for the drug. Our partner Asahi Kasei Pharma expects to obtain study results in the second half of 2021, which will be the next major milestone for potentially making Cresemba available for patients in Japan. ....

United States , Basel Stadt , Nils Schr , Asahi Kasei Pharma , David Veitch , Head Of Corporate Communications Investor Relations , European Union , Asahi Kasei Pharma Corporation , Swiss Exchange , Basilea Pharmaceutica Ltd , Chief Executive Officer , Latin America , Middle East , North Africa , Basilea Pharmaceutica , Corporate Communications , Public Assessment Report , Anti Fungal , ஒன்றுபட்டது மாநிலங்களில் , பேசல் ஸ்ட்யாட்ட் , டேவிட் வைச் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , ஐரோப்பிய தொழிற்சங்கம் , சுவிஸ் பரிமாற்றம் , தலைமை நிர்வாகி அதிகாரி , லத்தீன் அமெரிக்கா ,